Cargando…

Association between Gout, Urate-Lowering Therapy, and Risk of Developing Type 2 Diabetes Mellitus: A Nationwide Population-Based Retrospective Cohort Study

Gout is the most prevalent inflammatory arthritis in adults. Although the link between gout and type 2 diabetes mellitus (T2DM) has been documented, our understanding of the association between urate-lowering therapy (ULT) among gout patients and T2DM development remains poor. We included 69,326 pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Yi-Jen, Chung, Yun-Lung, Lin, Cheng-Li, Lim, Yun-Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407011/ https://www.ncbi.nlm.nih.gov/pubmed/32775432 http://dx.doi.org/10.1155/2020/6358954

Ejemplares similares

Effects of Urate-Lowering Therapy on Risk of Hyperlipidemia in Gout by a Population-Based Cohort Study and on In Vitro Hepatic Lipogenesis-Related Gene Expression
por: Fang, Yi-Jen, et al.
Publicado: (2020)

Variation in serum urate levels in the absence of gout and urate lowering therapy
por: Shaffer, Andrew, et al.
Publicado: (2021)

Adherence with urate-lowering therapies for the treatment of gout
por: Harrold, Leslie R, et al.
Publicado: (2009)

Urate‐lowering therapy for patients with gout on hemodialysis
por: Alkilany, Reem, et al.
Publicado: (2022)

Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England
por: Russell, Mark D, et al.
Publicado: (2022)

Effect of metformin use on clinical outcomes and serum urate in gout patients with diabetes mellitus: a retrospective cohort study
por: Veenstra, Frouwke, et al.
Publicado: (2022)

Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort
por: Ranieri, Laura, et al.
Publicado: (2018)

Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout
por: Yen, Fu-Shun, et al.
Publicado: (2021)

Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout
por: Lee, You-Hyun, et al.
Publicado: (2006)

Treatment approaches and adherence to urate-lowering therapy for patients with gout
por: Aung, Thanda, et al.
Publicado: (2017)

The Effect of Decrease in Serum Urate for the Risk of Gout Flares During Urate-Lowering Therapy Initiation Among Chinese Male Gout Patients: A Prospective Cohort Study
por: Pang, Lei, et al.
Publicado: (2023)

Urate in fingernail represents the deposition of urate burden in gout patients
por: Chen, Haibing, et al.
Publicado: (2020)

Urate-lowering treatment and risk of total joint replacement in patients with gout
por: Kuo, Chang-Fu, et al.
Publicado: (2018)

Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus
por: Chang, Hsin-Wen, et al.
Publicado: (2019)

Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study
por: Roughley, Matthew, et al.
Publicado: (2018)

Gout and the risk of dementia: a nationwide population-based cohort study
por: Hong, Jen-Yee, et al.
Publicado: (2015)

Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout
por: Yen, Fu-Shun, et al.
Publicado: (2020)

Urate-Lowering Therapy May Prevent the Development of Coronary Artery Disease in Patients With Gout
por: Yen, Fu-Shun, et al.
Publicado: (2020)

Association between Depression, Antidepression Medications, and the Risk of Developing Type 2 Diabetes Mellitus: A Nationwide Population-Based Retrospective Cohort Study in Taiwan
por: Fang, Yi-Jen, et al.
Publicado: (2021)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
por: Jackson, Robert L, et al.
Publicado: (2012)

High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
por: Perez-Ruiz, Fernando, et al.
Publicado: (2020)

Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review
por: Tabi-Amponsah, Adwoa Dansoa, et al.
Publicado: (2023)

Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
por: Pisaniello, Huai Leng, et al.
Publicado: (2018)

Atrial Fibrillation Risk and Urate-Lowering Therapy in Patients with Gout: A Cohort Study Using a Clinical Database
por: Liu, Ching-Han, et al.
Publicado: (2022)

Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients
por: Janssen, Carly A., et al.
Publicado: (2017)

Systemic Urate Deposition: An Unrecognized Complication of Gout?
por: Khanna, Puja, et al.
Publicado: (2020)

Interventions to improve uptake of urate-lowering therapy in patients with gout: a systematic review
por: Gill, Iqbal, et al.
Publicado: (2020)

Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients
por: te Kampe, Ritch, et al.
Publicado: (2022)

Replication of Gout/Urate Concentrations GWAS Susceptibility Loci Associated with Gout in a Han Chinese Population
por: Li, Zhiqiang, et al.
Publicado: (2017)

Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
por: Dalbeth, Nicola, et al.
Publicado: (2012)

Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients
por: Chung, Ting-Ting, et al.
Publicado: (2019)

Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort
por: Singh, Jasvinder A, et al.
Publicado: (2015)

Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
por: Singh, Jasvinder A
Publicado: (2014)

Assessing the sensitivity to change of the OMERACT ultrasound structural gout lesions during urate-lowering therapy
por: Christiansen, Sara Nysom, et al.
Publicado: (2020)

When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy
por: Choi, Hyon K., et al.
Publicado: (2022)

Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease
por: Mitri, Ghaith, et al.
Publicado: (2016)

Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
por: Kvasnička, Aleš, et al.
Publicado: (2023)

The relationship between ferritin and urate levels and risk of gout
por: Fatima, Tahzeeb, et al.
Publicado: (2018)

Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout
por: Tan, Philip K., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7inc88j8oepu0opsulktu4s9t7